Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.

In the Medical segment, sales rose by € 24.3 million or 27% to € 115.2 million compared to the previous year. The increase in sales was driven in particular by strong demand for radiopharmaceuticals. At € 130.9 million, sales in the Isotope Products segment remained at the previous year's level (€ 131.4 million).

For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million.

The full 2023 financial statements can be found here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz23e.pdf

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com